Hyperparathyroidism - 63 Studies Found
| Active, not recruiting |
: To Assess the Long-term Safety of AMG 416 in the Treatment of SHPT in Subjects With CKD on Hemodialysis : Hyperparathyroidism, Secondary : 2014-03-03 : Drug: AMG 416 Subjects will be administered IV AMG 416 at the end of their regular dialysis sessions on |
| Completed |
: Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism : Secondary Hyperparathyroidism : 2010-12-03 :
|
| Completed |
: Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT) : Secondary Hyperparathyroidism : 2009-01-22 :
|
| Completed |
: Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients : Secondary Hyperparathyroidism : 2015-01-11 : Drug: Combination Cinacalcet with Vitamin D analogue Depending on the iPTH level and the serum calcium l |
| Completed |
: LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients : Secondary Hyperparathyroidism : 2010-07-02 : Drug: LEO 27847 First in patient |
| Completed |
: Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation : Secondary Hyperparathyroidism : 2010-04-19 :
|
| Completed |
: A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism : Secondary Hyperparathyroidism : 2012-07-25 : Drug: DP001 DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks |
| Recruiting |
: Optimal Anemia Treatment in End Stage Renal Disease (ERSD) : Hyperparathyroidism, Secondary : 2014-06-27 :
|
| Terminated |
: Open-label Study to Assess the Long-term Safety and Efficacy of Etelcalcetide (Also Known as AMG 416 or KAI-4169) in Patients With Secondary Hyperparathyroidism : Secondary Hyperparathyroidism : 2012-04-05 : Drug: Etelcalcetide Administered as an intravenous bolus three times a week at the end of each hemodialy |
| Completed |
: ACHIEVE: Optimizing the Treatment of Secondary Hyperparathyroidism : Secondary Hyperparathyroidism : 2005-08-24 :
|